US WorldMeds, LLC Completes Phase III Trial of Lofexidine for Treatment of Opiate Withdrawal Symptoms

LOUISVILLE, Ky.--(BUSINESS WIRE)--US WorldMeds, a Kentucky-based specialty pharmaceutical company, today announced that a recently completed Phase III clinical trial investigating the use of lofexidine hydrochloride (Lofexidine) for the treatment of opiate withdrawal symptoms in patients undergoing opiate detoxification has shown that opiate-dependent patients taking the drug experienced a significant reduction in withdrawal symptoms at the anticipated peak of withdrawal and stayed longer in detoxification treatment as compared to patients taking placebo.